Tadalafil is available in more than one oral dosage form, but the dosage form alone does not tell you the product's indication or treatment framework. Tablets are the most familiar form and appear across ED/BPH and PAH product contexts, while an FDA-approved oral suspension exists specifically within the PAH branch.
A formulation describes more than the amount of tadalafil present. It includes the physical dosage form and the combination of active and inactive ingredients used to deliver the drug, so a tadalafil tablet and a tadalafil suspension can contain the same active molecule while remaining different finished pharmaceutical products.
This page maps those dosage-form relationships without duplicating the detailed strength, brand or dosing pages. Tablet-specific questions belong on Tadalafil Tablets, liquid-product questions on Tadalafil Oral Suspension, and strength architecture on Tadalafil Strengths.
The current U.S. tadalafil landscape can be organized first by dosage form and then by product context. Tablets span multiple branded and generic pathways, while the FDA-approved oral suspension represented here by Tadliq belongs to the PAH context.
The table intentionally identifies dosage form and labeled context rather than reproducing every available strength or product presentation.
| Dosage Form | Product Examples | Labeled Context | Deep Dive |
|---|---|---|---|
| Oral tablet | Cialis and corresponding generic tadalafil tablets | ED, BPH and combined ED/BPH depending on the applicable product label | Tadalafil Tablets |
| Oral tablet | Adcirca and corresponding PAH tadalafil tablet products | Pulmonary arterial hypertension, WHO Group 1 | Adcirca |
| Oral suspension | Tadliq | Pulmonary arterial hypertension, WHO Group 1 | Tadalafil Oral Suspension |
A pharmaceutical formulation is the finished design used to deliver tadalafil. It includes the active ingredient together with excipients and a physical dosage form such as a tablet or suspension.
Formulation therefore answers a different question from strength. A tablet and a suspension can both contain tadalafil while differing in physical form, inactive ingredients, administration steps and product labeling.
| Term | What It Describes |
|---|---|
| Active ingredient | The drug molecule: tadalafil |
| Formulation | The finished pharmaceutical composition used to deliver tadalafil |
| Dosage form | Physical form such as tablet or oral suspension |
| Strength | Amount or concentration of tadalafil in a dosage unit |
| Brand | Proprietary identity of a particular finished product |
| Indication | The labeled condition or use associated with that product |
Oral tablets form the largest and most familiar part of the tadalafil product landscape. Current U.S. labeling includes Cialis tablets in the ED/BPH context, Adcirca tablets in the PAH context and numerous generic tadalafil tablet products.
The shared tablet format does not make these products one universal medicine. Their labeled indications, available strengths and regimen structures still depend on the specific product and regulatory pathway.
Tablet design and product-specific handling are covered on Tadalafil Tablets.
| Tablet Context | Example | What Defines It Beyond Being a Tablet? |
|---|---|---|
| ED/BPH | Cialis | Cialis labeling and its ED/BPH treatment frameworks |
| ED/BPH generic | Generic tadalafil tablets | Reference product, approved labeling and manufacturer |
| PAH | Adcirca | PAH-specific labeling and treatment framework |
| PAH generic | Generic tadalafil referencing an appropriate PAH product | PAH reference-product and labeling context |
Cialis is a brand name for a tadalafil tablet product rather than a synonym for the tablet dosage form itself. Current U.S. Cialis labeling places the product in ED, BPH and combined ED/BPH treatment contexts.
Other tadalafil tablets can contain the same active ingredient without being Cialis. The molecule-brand relationship is explained on Tadalafil and Cialis, while the dedicated Cialis page owns brand-specific product detail.
| Statement | Interpretation |
|---|---|
| Cialis contains tadalafil | Correct |
| Cialis is an oral tablet product | Correct |
| Every tadalafil tablet is Cialis | Incorrect |
| Tablet is a brand name | Incorrect; tablet describes a dosage form |
FDA-approved generic tadalafil products are widely represented by oral tablets in the ED/BPH market, and current generic labels commonly include multiple tablet strengths. Generic tablets may differ in appearance, excipients, manufacturer and packaging while containing tadalafil as the active ingredient.
The fact that a product is a tablet does not by itself establish which reference product or indication it belongs to. Generic identity and regulatory equivalence are covered on Generic Tadalafil and Tadalafil Bioequivalence.
| Generic Tablet Feature | What May Be Shared or Differ |
|---|---|
| Active ingredient | Tadalafil |
| Dosage form | Tablet |
| Appearance | May differ by manufacturer |
| Inactive ingredients | May differ within regulatory requirements |
| Reference product | Must be identified from the relevant generic approval context |
Adcirca demonstrates why dosage form and indication must be separated. It contains tadalafil in tablet form, but its current U.S. labeling is centered on pulmonary arterial hypertension rather than the ED/BPH uses associated with Cialis.
Current Adcirca labeling identifies 20 mg non-scored tablets and a PAH treatment framework built around those tablets. Detailed dosing belongs on the product and dosage pages rather than this formulation hub.
For the drug-brand relationship, see Tadalafil and Adcirca.
| Adcirca Feature | Formulation Context |
|---|---|
| Active ingredient | Tadalafil |
| Dosage form | Oral tablet |
| Current tablet strength | 20 mg |
| Labeled disease context | PAH, WHO Group 1 |
| Same product as Cialis | No |
Tadliq expanded the U.S. tadalafil product landscape beyond tablets. FDA approved it as tadalafil oral suspension under its own NDA, and its current labeling places the product in the treatment of pulmonary arterial hypertension, WHO Group 1, to improve exercise ability.
The suspension contains tadalafil in a liquid vehicle rather than in a solid tablet matrix. That makes it a different dosage form and formulation even though the active drug remains tadalafil.
The liquid formulation is examined in depth on Tadalafil Oral Suspension and the finished product on Tadliq.
| Tadliq Feature | Product Context |
|---|---|
| Active ingredient | Tadalafil |
| Dosage form | Oral suspension |
| Concentration | 20 mg/5 mL |
| Route | Oral |
| Labeled disease context | PAH, WHO Group 1 |
| Regulatory pathway | Separate NDA product |
Adcirca tablets and Tadliq suspension illustrate the difference particularly clearly because both belong to the PAH branch and both deliver tadalafil orally, yet their dosage forms and formulations are different. FDA's quality review for Tadliq explicitly notes that its dosage form, formulation and composition differ from the listed Adcirca tablet product.
A dosage-form difference therefore does not require a different active molecule. It changes how the finished product is constructed, measured and administered while the active pharmaceutical ingredient remains tadalafil.
A direct formulation comparison is available on Tadalafil Tablets vs Oral Suspension.
| Feature | Tablet | Oral Suspension |
|---|---|---|
| Active drug | Tadalafil | Tadalafil |
| Physical form | Solid unit | Liquid suspension |
| Typical measurement | Number of tablets | Measured liquid volume |
| Product example | Adcirca | Tadliq |
| Oral route | Yes | Yes |
| Same finished formulation | No | No |
Strength quantifies how much tadalafil a dosage unit contains, while formulation identifies how the medicine is physically and compositionally presented. A tablet strength is expressed as an amount per tablet, whereas a suspension can be expressed as an amount of tadalafil per volume.
Because these concepts answer different questions, a formulation page should not be used as the primary guide to all available milligram options. That information belongs on Tadalafil Strengths.
| Question | Concept |
|---|---|
| Is the medicine a tablet or a suspension? | Dosage form |
| What ingredients and physical system make up the product? | Formulation |
| How much tadalafil is in one tablet? | Tablet strength |
| How much tadalafil is present per volume of liquid? | Suspension concentration |
| Which condition is the product labeled for? | Indication |
Several products can use the same dosage form without becoming the same brand. Cialis, Adcirca and many generic tadalafil products are tablets, but they remain different finished-product identities.
The reverse is also useful: knowing that a product contains tadalafil does not tell you whether it is a tablet or oral suspension. Product identity has to be read from the actual label rather than inferred from the active-drug name.
| Information Known | What You Still Cannot Assume |
|---|---|
| The product contains tadalafil | Its brand, dosage form or indication |
| The product is a tadalafil tablet | That it is Cialis |
| The product is used in PAH | That it is necessarily Adcirca rather than another PAH tadalafil product |
| The product is an oral suspension | That all tadalafil products can be used in the same way |
Tadalafil tablets appear in more than one disease context. Cialis-type tablets can be labeled for ED, BPH and combined ED/BPH, while Adcirca-type tablet products belong to PAH.
This means that 'tadalafil tablet' is not a complete therapeutic description. The product label, reference product and indication remain necessary to understand how that formulation fits clinically.
For the broader indication map, see Tadalafil Uses.
| Dosage Form | Example Context | Example Product |
|---|---|---|
| Tablet | ED / BPH / ED+BPH | Cialis or corresponding generic tadalafil |
| Tablet | PAH | Adcirca or corresponding PAH tadalafil tablet |
| Oral suspension | PAH | Tadliq |
Different dosage forms can require different product-specific handling even when they contain the same active ingredient. Current Cialis labeling instructs that the tablets should not be split, Adcirca describes its tablets as not scored, and Tadliq labeling instructs users to shake the bottle well for 30 seconds before measuring a dose.
These are formulation-specific instructions rather than general properties of the tadalafil molecule. Patients should therefore follow the labeling for the actual product supplied rather than transferring handling instructions from one tadalafil formulation to another.
| Product Example | Dosage Form | Formulation-Specific Handling Example |
|---|---|---|
| Cialis | Tablet | Current label says not to split the tablets |
| Adcirca | Tablet | Current tablets are described as not scored |
| Tadliq | Oral suspension | Shake well for 30 seconds before measuring the dose |
Tadliq is the proprietary identity of a specific FDA-approved tadalafil oral suspension. The word should not be used as though it were the generic dosage-form name for every liquid preparation that might contain tadalafil.
Likewise, an individually compounded liquid and an FDA-approved finished oral-suspension product are not automatically the same pharmaceutical product. Product source, formulation, concentration, labeling and regulatory status all matter.
| Term | Meaning |
|---|---|
| Tadalafil oral suspension | General dosage-form description |
| Tadliq | Specific FDA-approved branded tadalafil oral suspension |
| Compounded tadalafil liquid | A separately prepared formulation that should not automatically be equated with Tadliq |
A liquid dosage form provides a different administration format from a solid tablet. FDA's quality review of Tadliq described the suspension as a new tadalafil dosage form and noted that it was intended to provide an oral formulation that could be easier to administer for patients who have difficulty swallowing tablets.
That formulation advantage does not change the drug into a new active ingredient or extend the product automatically into ED or BPH. Tadliq remains a product-specific PAH formulation.
| Question | Answer |
|---|---|
| Does the suspension contain a different active drug? | No; the active drug is tadalafil |
| Is the physical form different from a tablet? | Yes |
| Can a liquid form help when swallowing tablets is difficult? | That was part of the rationale described in FDA's product-quality review |
| Does the liquid form automatically carry ED/BPH labeling? | No |
Two products containing the same active molecule cannot be assumed to have identical pharmaceutical performance solely because the ingredient name matches. Dosage-form composition, release characteristics and administration method can affect how regulators evaluate a product.
For Tadliq, FDA's review relied partly on the agency's previous finding of safety and effectiveness for Adcirca while also considering supporting in-vivo bioavailability information for the new oral suspension. This illustrates why formulation questions and bioequivalence or bioavailability questions overlap without being the same concept.
The regulatory exposure comparison is covered separately on Tadalafil Bioequivalence.
| Question | Why It Matters |
|---|---|
| Same active ingredient? | Establishes the drug molecule |
| Same dosage form? | Determines whether the physical presentation matches |
| Same formulation and composition? | May affect pharmaceutical performance and product evaluation |
| Bioavailability / bioequivalence evidence? | Helps characterize or compare systemic delivery in the applicable regulatory pathway |
Tadalafil is the active ingredient, but finished products also contain inactive ingredients that help create the tablet or suspension and maintain product performance. Those excipients can differ between brands, generics and dosage forms without changing tadalafil's chemical identity.
A suspension needs a liquid formulation capable of maintaining the drug in an appropriate dispersed state, whereas a tablet requires a solid matrix and coating or manufacturing system. Exact inactive-ingredient lists should be taken from the label for the specific product rather than generalized across all tadalafil medicines.
| Formulation Component | Role |
|---|---|
| Tadalafil | Active pharmaceutical ingredient |
| Tablet excipients | Support manufacture, stability, disintegration and other product properties |
| Suspension excipients | Support the liquid vehicle, dispersion, stability and palatability |
| Product-specific ingredient list | Defines the actual formulation supplied by that manufacturer |
The principal tadalafil formulations discussed here are orally administered. Current Cialis and Adcirca labeling permits their tablets to be taken without regard to food, and Tadliq's label similarly permits administration with or without food.
That similarity should not be interpreted as proof that the formulations are otherwise identical. Route and food instructions are only part of the overall product design and label.
| Product Example | Route | Food Context |
|---|---|---|
| Cialis | Oral | May be taken without regard to food |
| Adcirca | Oral | May be taken with or without food |
| Tadliq | Oral | May be taken with or without food |
Storage is a finished-product property rather than a universal consequence of the tadalafil molecule. Tablet and suspension labels specify their own storage and handling requirements because stability depends on the actual formulation, packaging and dosage form.
Patients should therefore use the storage directions supplied with their medication rather than assume that every tadalafil product has identical handling requirements. The broader topic is covered on Tadalafil Storage.
| Storage Question | Where to Check |
|---|---|
| Temperature range | Specific product label |
| Container requirements | Specific product label |
| Need to shake before use | Suspension-specific instructions |
| General tadalafil storage concepts | Tadalafil Storage |
A tadalafil tablet and a tadalafil oral suspension share the same active molecule but should not be assumed to be interchangeable simply by matching the total number of milligrams. The actual product label, indication, dosage form, concentration and regulatory context all matter.
This is especially important across Cialis-type ED/BPH products and PAH products. Formulation choice should follow the prescribed product rather than being reconstructed by converting one tadalafil product into another based only on the active ingredient.
| Shared Feature | Still Must Be Checked |
|---|---|
| Tadalafil active ingredient | Specific product identity |
| Oral route | Dosage form |
| PDE5-inhibiting pharmacology | Indication |
| Milligram amount | Concentration, regimen and labeling |
Tadalafil formulation should not be selected in isolation from the condition being treated and the product that has been prescribed. ED/BPH treatment is represented primarily by tadalafil tablets, whereas the current U.S. oral-suspension example belongs to the PAH branch.
Once the appropriate product context is established, dosage form, strength and administration instructions can be interpreted together. Dose-level questions belong on Tadalafil Dosage, while indication-specific frameworks are covered on Tadalafil for Erectile Dysfunction and Tadalafil for Pulmonary Hypertension.
| Step | Question |
|---|---|
| 1 | Which condition and product context apply? |
| 2 | Which approved product has been prescribed? |
| 3 | What dosage form does that product use? |
| 4 | What strength or concentration applies? |
| 5 | What product-specific administration instructions apply? |
Most formulation errors come from collapsing several product attributes into one concept. A strength is not a formulation, a tablet is not automatically Cialis, and the existence of a tadalafil oral suspension does not mean there is a general liquid ED version of every tadalafil product.
Separating active ingredient, dosage form, brand, strength and indication prevents those assumptions.
| Misunderstanding | More Accurate Interpretation |
|---|---|
| "Tadalafil only comes as tablets" | An FDA-approved tadalafil oral suspension also exists in the PAH context |
| "Every tadalafil tablet is Cialis" | No; Cialis, Adcirca and generic tadalafil can all use tablet dosage forms |
| "Adcirca is a different active drug because it is a PAH product" | No; its active ingredient is tadalafil |
| "Tadliq is a liquid version of Cialis for ED" | No; Tadliq is a separate tadalafil oral-suspension product labeled for PAH |
| "Strength and formulation mean the same thing" | No; strength measures drug amount or concentration, while formulation describes the finished pharmaceutical product design |
| "The same milligram amount makes two tadalafil formulations interchangeable" | No; product identity, dosage form, labeling and indication still matter |
The main U.S. tadalafil dosage forms discussed in current labeling are oral tablets and an oral suspension. Tablets appear across Cialis, Adcirca and generic tadalafil products, while Tadliq is an FDA-approved tadalafil oral suspension in the PAH context.
Yes. Oral tablets are the most common and widely represented tadalafil dosage form, including Cialis, Adcirca and many generic tadalafil products.
Yes. Tadliq is an FDA-approved tadalafil oral suspension containing 20 mg per 5 mL and is labeled for pulmonary arterial hypertension, WHO Group 1.
No. Cialis is a branded tadalafil tablet product in the ED/BPH context. Tadliq is a separate branded tadalafil oral suspension in the PAH context.
No. Both contain tadalafil and belong to the PAH treatment context, but Adcirca is a tablet product and Tadliq is an oral suspension with its own NDA and formulation.
Dosage form describes the physical form, such as a tablet or suspension. Formulation is broader and includes the active drug, inactive ingredients and pharmaceutical design used to create that finished dosage form.
No. Strength describes how much tadalafil is present in a tablet or specified volume, while formulation describes the finished pharmaceutical composition and dosage form.
No. Cialis, Adcirca and numerous generic tadalafil products all use tablet dosage forms, but they are different finished products and can belong to different indication contexts.
They both contain tadalafil in tablet form, but they are separate finished products with different labeling and product contexts. Sharing the active ingredient and dosage-form category does not make them the same product.
Yes. Both use the oral route and contain tadalafil, but Adcirca is a tablet and Tadliq is an oral suspension.
Tadliq is a suspension, so the label instructs users to shake the bottle well for 30 seconds before measuring a dose. That is a formulation-specific handling requirement rather than a general property of tadalafil.
Current Cialis labeling instructs that the tablets should not be split and that the entire dose should be taken. Product-specific instructions should be followed for the actual tadalafil medicine supplied.
FDA's review of Tadliq described the liquid dosage form as intended to provide another administration format, including for patients who may have difficulty swallowing tablets. Its approved context remains PAH.
No. Tadalafil remains the active ingredient. What changes is the dosage form, formulation, composition and product-specific administration context.
Yes. Tadalafil tablets appear in ED/BPH and PAH product contexts. The dosage form alone therefore does not identify the indication.
No. Matching the amount of tadalafil does not by itself establish interchangeability. Product identity, dosage form, indication, concentration, reference product and labeling must also be considered.
Yes. Different branded, generic and dosage-form products can use different excipients while containing tadalafil as the active ingredient.
The current tablet and Tadliq suspension products discussed here are administered orally. They can share the oral route while remaining different dosage forms and formulations.
The dedicated Tadalafil Strengths page covers milligram and concentration options in more detail. Formulation and strength are related product attributes but are not the same concept.